Introduction

Forkhead box (Fox) genes are a superfamily of evolutionarily conserved transcriptional regulators clustered by the similarities in their Forkhead (FKH) or Winged Helix (WHD) DNA-binding domain. Fox proteins are grouped into sub-classes from FoxA to FoxS. These proteins are involved in a wide range of biological processes, such as development, differentiation, proliferation, apoptosis, migration and invasion [1].

Among the Fox proteins, accumulating evidence has associated FoxM1 overexpression with a wide range of cancers, including breast cancer, colorectal cancer, lung, medulloblastoma, glioblastoma, pancreatic cancer and leukemia [2-8]. To support the FoxM1 role in cancer, several groups have examined the cellular effects of FoxM1 overexpression or inhibition. Furthermore, recent data have revealed that FoxM1 is often associated with cancer patients or cell lines that exhibit chemotherapeutic resistance [5,9]. Therefore, understanding intrinsic FoxM1 regulation and function has become an important target to better comprehend cancer cell proliferation, progression and drug resistance.

Constitutive FoxM1 activation has been shown to play a significant role in cell cycle control. FoxM1 controls the expression of critical genes regulating the G1/S transition, such as SKP1, CCND1 and CSK1, and the G2/M progression, such as CCNB1 and CDC25B [10]. Furthermore, FoxM1 up-regulates AURKA expression, which is essential to mitotic spindle assembly during mitosis [11]. Although some of these data point to a cell cycle regulatory function for FoxM1, recent published data suggest other functions in which it could play a role. However, the understanding of FoxM1 transcriptional activation and the role of FoxM1 as an oncogene is limited.

To date, some studies have revealed that FoxM1 expression can be driven primarily by the Hedgehog signaling pathway in gastric cancer [12], colorectal cancer [13], meningioma [14] and breast cancer [15]. Moreover, FoxM1 has been proposed as a Ras/MEK/MAPK signaling target [16,17]. Although some data have revealed FoxM1 as regulated by Hedgehog and Ras signaling pathways in solid cancer, FoxM1 regulation in leukemia, mainly in chronic leukemia, is poorly understood.

FoxM1 and STAT3 are often related to cancer and present similar consequences when overexpressed or inhibited [1,18]. In a recent publication, we demonstrate that STAT3 is crucial to proliferation and inhibits apoptosis in the leukemic K562 cell line [19]. Although the STAT3 protein was first described as a member of the Jak/Stat signaling pathway, in some cancer cells STAT3 is also activated by non-Jak/Stat proteins, such as BCR-ABL, c-Abl, MEK1, Src and Smoothened. This fact links FoxM1 activation to STAT3 signaling [20,21].

In this study, we sought to characterize the role and relationship between FoxM1 and STAT3 proteins in a cell line with constitutively activated STAT3, known as K562. First, we analyzed STAT3 as a transcriptional factor for FoxM1 gene expression. Additionally, we evaluated the FoxM1 expression profile in a chemoresistant-derived K562/R cell line, which...
exhibits chemoresistance to imatinib, the most common drug used to treat chronic myeloid leukemia (CML). Finally, to increase our understanding of the role FoxM1 in our cancer model, we analyzed the overall gene expression changes in FoxM1-depleted K562 cells.

**Results**

Identification of STAT3 binding consensus sequences and validation of STAT3 protein binding at the FoxM1 gene promoter

DNA sequence analysis of 1000 base pairs (bp) from the FoxM1 promoter revealed five consensus sequences for STAT protein binding (table 1). However, only one of these five putative STAT sites aligns comprehends to the STAT3 binding consensus sequence. The potential STAT3 binding site is located at positions from nucleotide –167 up to –178 bp upstream of the transcription starting site (figure 1A). To verify whether there is STAT3 binding to the STAT3-binding consensus sequences on the FoxM1 promoter in vitro and in vivo, electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) assays were performed using a constitutive STAT3 activated cell line, K562. Using the EMSA assay, we validated the STAT3 in vitro interaction with a radiolabeled DNA probe designed from the FoxM1 promoter sequence, which contains a STAT3 binding sequence (figure 1B). Furthermore, to confirm the previous results, K562 cells were treated with 40 μM of LLL-3, a STAT3 dimerization inhibitor. STAT3 dimer inhibition abrogated the STAT3-DNA interaction, suggesting specific STAT3 protein binding at the STAT3-consensus sequence from the FoxM1 promoter (figure 1B). Additionally, the ChIP assay indicated a positive in vivo STAT3 interaction with the consensus sequence from the FoxM1 promoter. Using ChIP, we amplified STAT3 in immunoprecipitated DNA fragments and found approximately 33% of the input DNA using primers specific to the FoxM1 promoter DNA sequence (figure 1C). Although the binding sequence of STAT3 is very specific, we evaluated the proximal general STAT binding sites by amplification these regions in the immunoprecipitated STAT3 DNA fragments. To these experiments, we amplified a known STAT3 target gene, CDC25A, as positive control of immunoprecipitation [22]. Our results shown that our studied STAT3 binding site of FoxM1, –440/–432 bp, and of CDC25A gene, –222/–250 bp, was preferentially amplified in STAT3 immunoprecipitated DNA in comparison to others proximal STAT binding sites (figure S1). In summary, all of the experimental assays suggested the binding of the STAT3 protein to the FoxM1 gene promoter.

FoxM1 gene expression is directly dependent on STAT3 activation

To assess whether STAT3 could serve as a FoxM1 transcriptional activator, we compared the FoxM1 mRNA levels using RT-qPCR following STAT3 inhibitor treatment. The levels of the FoxM1 transcripts were assessed using K562 cells treated with STAT3 inhibitors, LLL-3 to directly inhibit STAT3 or imatinib to indirectly inhibit STAT3 activation by blocking BCR-ABL signaling. At 24 h after treatment with 40 μM of LLL-3 or 1 μM of imatinib, our results indicated that FoxM1 mRNA levels decreased 4-fold in response to the LLL-3 treatment and 3-fold in response to the imatinib treatment when compared to the untreated controls (figure 2A). These results suggest that FoxM1 mRNA levels are dependent on STAT3 activity and BCR-ABL signaling.

To evaluate whether STAT3 is involved in regulating the FoxM1 DNA promoter sequence in vivo, we cloned the FoxM1 DNA promoter region containing the STAT3 binding site, as described in Table 1, into a luciferase reporter gene construct. Our results confirm our hypothesis that STAT3 regulates the transcription of luciferase gene and STAT3 inhibition with LLL-3 or imatinib suppresses the luciferase signal. Cloned FoxM1 DNA promoter increased the luciferase signal by 15% compared to empty vector (figure 2C). Inhibition of STAT3 using 40 μM of LLL-3 or 1 μM of imatinib for 24 h in K562 cells decreased the luciferase signal by approximately 11% and 8%, respectively, compared to untreated cells (figure 2C). Our results indicate that the majority of luciferase signal was promoted by STAT3 transcriptional factor activity, which indicates that STAT3 is an important regulator of the FoxM1 DNA promoter region.

FoxM1 is crucial to K562 cell proliferation and survival

To determine whether FoxM1 could be related to the rate of K562 cell proliferation, FoxM1 expression was depleted by a RNA interference (siRNA) assay. First, FoxM1 transcript levels were assessed after transfection by RT-qPCR to evaluate the percentages of inhibition. FoxM1 mRNA levels were significantly inhibited, on average, 60%, 75% and 85% at 24, 48 and 72 h, respectively, when siRNA was used at a 10 nM concentration (figure 2A). We then investigated the effects of FoxM1 on the K562 cell proliferation ratio. Our results showed that FoxM1 inhibition culminates in blocking K562 cell proliferation by approximately 50% and 75% at 48 and 72 h, respectively, compared to the control or scrambled-transfected K562 cells (figure 2B). These results suggest that FoxM1 appears to be crucial for K562 cell proliferation. To determine whether this decrease is related to a loss of viability or cell cycle progression, annexin-V and propidium iodide (PI) tests were performed to assess apoptosis and to evaluate DNA content to determine the cell cycle phases in the FoxM1-depleted K562 cells. In the apoptosis assays, the percentage of apoptotic cells after 24, 48 and 72 hours of silencing was 8% (±2.5%), 10% (±2.15%) and 14% (±3.04%), respectively, when comparing FoxM1 inhibited with scrambled-transfected K562 cells (figure 2C). These data suggest that FoxM1 is essential to K562 cell viability. Our cell cycle analysis showed that the cells remained without significant changes between the cell cycle phases during the transfection periods. Our results indicated that overall, approximately 60% of the cells were in the G1 cell cycle phase, approximately 20% were in the S phase and 20% were in the G2 phase in both the siRNA-scrambled-treated and siRNA-FoxM1-treated cells (figure 2D). At 48 h and 72 h after FoxM1 depletion, we observed a tiny accumulation G2 phase K562 cells compared to siRNA-scrambled-treated. These results suggest that FoxM1 inhibition in K562 cells reduces cell viability and does not promote the accumulation of cells in a specific phase of the cell cycle.

Chemotherapeutic drug resistant K562 cells exhibit high expression of FoxM1

Elevated expression of FoxM1 has been extensively reported in several solid tumor types and specifically has been closely related to cancer chemotherapeutics resistance [23]. However, the understanding of the role of FoxM1 drug resistance in leukemia is poorly known. To further investigate this issue, we evaluated FoxM1 expression in a chronic myeloid leukemia K562 cell line and in the related resistant cell line, K562-R. We also evaluated the STAT3 mRNA levels to investigate STAT3 expression and its correlation with FoxM1 levels. The relative mRNA levels were measured by RT-qPCR assay. Our tests showed that FoxM1...
mRNA was increased 2.7 fold in K562-R cells when compared to K562 cells (figure 2B). Similarly, STAT3 mRNA levels were also elevated by approximately 2.5 fold in imatinib-resistant K562-R cells compared to K562 cells (figure 2B). Similar to existing data concerning solid tumors, our data suggests that FoxM1 and STAT3 mRNA levels are concomitantly overexpressed in leukemia-resistant K562-R cells.

Microarray analysis reveals the full role of FoxM1 in the modulation of the cell cycle and for transcription of genes involved in DNA repair

To identify the gene targets of the FoxM1 transcriptional factor, we compared the expressed gene changes by comparing the K562 cells depleted of FoxM1 by siRNA with the scrambled-siRNA transfected K562 cells using microarray analysis. The data from the up-regulated and down-regulated differentially expressed genes were submitted to determine the signaling pathway mapping using Ingenuity Pathway analysis (IPA). Our results showed a total of 1668 genes downregulated and 1397 genes up-regulated in K562 cells depleted of FoxM1 when compared to the scrambled-siRNA-transfected K562 cells. We list our chip array results, which includes all genes that are altered as a consequence of FoxM1 interference (table S1). Through the IPA analysis, we selected the most significant biological processes and molecular function altered (tables 2, 3, and figures S3 and S4). The down-regulated genes were primarily clustered in the cell cycle processes (including cell cycle checkpoints, mitotic assembly and DNA duplication), the DNA repair pathways (including BRCA1 in DNA damage response and ATM signaling), protein ubiquitination and hereditary breast cancer signaling (Figure S3). The up-regulated genes were grouped into similar processes, such as cell cycle and DNA repair pathways (figure 5 and figure S4). However, the up-regulated genes also included genes in the embryonic stem-cell pathways, G protein signaling and others. Our results and analysis indicate that FoxM1 is involved in the regulation of genes from

Table 1. Putative STAT binding sites on FoxM1 gene promoter.

| Site number | Location relative to ATG | Consensus sites TTN (4–6)AA |
|-------------|--------------------------|-----------------------------|
| 1           | −160/−150                | TTCCCCCACAA                 |
| 2           | −440/−432                | TTAGTCCTAA*                 |
| 3           | −600/−593                | TTGTCTACAA                  |
| 4           | −617/−610                | TTGCTCCTAA                  |
| 5           | −730/−721                | TTGATTAAAA                  |

*consensus sequence of STAT3 (TTMN5(4–6)AA): M = A or C; D = A, G or T; N = any nucleotide. Transcriptional start site was determined by FoxM1 sequence (NM_202002).

doi:10.1371/journal.pone.0048160.t001
distinct cellular processes, but primarily regulates cell cycle and DNA repair.

**FoxM1 coordinates cell cycle gene expression**

To validate the gene expression changes detected by the microarray analysis and to focus on the most changed biological process, the cell cycle, we analyzed the mRNA levels of the genes involved in the cell cycle by RT-qPCR. We evaluated the mRNA level changes of **SKP2** from the G1/S transition, **CCNB1** and **CDC25B** from the G2/M transition and **AURKA** from the mitosis progression. Our results demonstrated that from 24 to 72 hours after the siRNA-FoxM1 transfections, **CDC25B** and **AURKA** mRNA levels were decreased by approximately 2 and 3 fold, respectively, compared to the scrambled-siRNA-treated cells (**figure 4B, 4C**). However, the SKP2 mRNA levels of the siRNA-FoxM1-transfected cells became significantly decreased after 48 to 72 hours by approximately 2 fold in comparison to the scrambled-RNA-treated cells (**figure 4C**). Moreover, following siRNA-FoxM1 transfection, the CCNB1 mRNA levels were significantly decreased (4 fold) compared to scrambled-RNA-treated cells at 72 hours (**figure 4A**). The microarray results demonstrate that CCNB1, CDC25B and SKP2 mRNA levels were decreased approximately 2 fold, and the AURKA mRNA levels were decreased approximately 3.2 fold following siRNA-FoxM1 transfection (**figure S2**). Our RT-qPCR results validate the differential changes in mRNA levels found through our microarray analyses because these two methodologies showed similar alterations in the mRNA levels of these genes. Additionally, these data suggest that FoxM1 could act as a transcriptional activator of the genes important to cell-cycle progression.

**Discussion**

Several signaling pathways have been involved in CML disease, and STAT3 activation is crucial for the survival and proliferation of CML cells [17,19]. The majority of CML-active signaling pathways promote direct or indirect STAT3 activation. In this scenario, STAT3 is classically activated by JAK/STAT but can also be activated by the crosstalk of another signal, such as MEK from Ras/Raf/MAPK [20] or by Smoothened from Sonic Hedgehog (Shh) signaling [21].
Additionally, FoxM1 is directly related to cells that have high proliferation rates, such as embryonic and cancer cells, but is mainly expressed in solid tumors [24]. Although FoxM1 has been proposed to be essential for a myriad of solid tumor cancers, the mechanisms that control FoxM1 expression and the role of FoxM1 in leukemia have not been fully elucidated. Because STAT3 and FoxM1 are overexpressed in similar cancer types and coordinate similar cellular mechanisms, we investigated the relationship between FoxM1 and STAT3.

Using FoxM1 gene promoter analyses, we identified several STAT consensus-binding sequences and one STAT3-specific consensus sequence, which we demonstrated to be functional using EMSA, ChIP, and luciferase reporter assay. Moreover, our results determined that FoxM1 expression is STAT3 dependent. To date, FoxM1 has also been reported as a target of the Shh or Ras/Raf/MAPK pathways [17,23], which are the same pathways that activate STAT3. Therefore, we hypothesize that STAT3 can act as a transducer of Shh and Ras signaling for FoxM1 expression. Therefore, this is the first report that describes FoxM1 as a direct STAT3 gene target.

The activation of both Shh and Ras pathways, as well as STAT3, have been associated with drug resistance in CML [25,26]. Our K562-R cells, which are more resistant to drug treatment than the K562 cells, exhibited a similar overexpression of both FoxM1 and STAT3. In addition to STAT3, FoxM1 has been associated with drug resistance. Therefore, STAT3 and FoxM1 may be involved in CML drug resistance. However, more investigations are needed to confirm its role in this mechanism. The establishment of FoxM1 as a STAT3 gene target could connect STAT3 signaling to cancer-related cellular processes, such as increased proliferation, survival, and drug resistance.

Figure 3. FoxM1 mRNA depletion inhibits proliferation and induces apoptosis. (A) Means (± standard deviation) of relative mRNA levels of inhibition of FoxM1 at 24, 48, and 72 h. (B) Proliferation of K562 cells (CTRL) compared to Scrambled and K562 FoxM1 depleted cells (siFoxM1 10 nM) at 24, 48, and 72 h. (C) Apoptosis analysis of K562 (CTRL, white bars), Scrambled-transfected K562 cells (cyan bars) and K562 FoxM1 depleted cells (black bars) at 24, 48, and 72 h.

doi:10.1371/journal.pone.0048160.g003

FoxM1 Gene Is a New STAT3 Target

PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e48160
appear do not interfere in the cell cycle checkpoints of K562 cells but reduce the number of critical genes required for these steps.

In addition to the arrest of cell cycle progression, our data demonstrated a loss of K562 cell viability in the absence of FoxM1. A prolonged cell cycle checkpoint has often been

Figure 4. Cell cycle and checkpoint genes are deregulated by FoxM1 inhibition. (A, B, C, D) Means (± standard deviation) of relative CCNB1, AURKA, SKP2, CDC25B mRNA levels of inhibition of K562 FoxM1 depleted cells at 24, 48 and 72 h. (E) Cell cycle content analysis (E), G1 phase, S phase, G2 phase, by Flow Cytometer. Two-way Anova test p<0.05. doi:10.1371/journal.pone.0048160.g004
accompanied with a loss of viability by triggering programmed cell death [32]. Although our microarray and pathway analysis results confirmed that FoxM1 primarily regulates the cell cycle, this present study also demonstrate the involvement of FoxM1 in DNA repair in leukemic cells. Recently, FoxM1 signaling was described as essential for coordinating cell cycle progression and DNA repair in ovarian cancer [33]. Furthermore, several data suggest that FoxM1 overexpression promotes genomic instabilities [34,35]. Our DNA repair pathway was mainly conducted by BRCA1 signaling, which is associated with a non-homologous end-joining repair, considered an error-prone repair [36]. Therefore, FoxM1 overexpression promotes proliferation and the DNA repair mechanisms that allow K562 cell survival and increase genomic instability. Although the role of FoxM1 in cellular proliferation has been extensively described, its function in DNA repair can be expanded to increase the understanding of the role of FoxM1 in maintaining DNA integrity and to understand CML disease progression.

CML is basically subdivided into the chronic phase (CP), the accelerate phase (AP) and the advanced stage, known as the blastic phase (BP); the BP has a poor prognosis and usually is fatal [37]. The progression from CP to BP has been related to genetic instability, which accumulates genetic abnormalities in the course of disease evolution [38]. Although BCR-ABL signaling contributes to CML development, little is known concerning disease evolution. It has been reported that Shh and Smoothened, which are both members of the Shh pathway, were overexpressed in the blastic phase compared to the chronic phase [39]. Because STAT3

**Figure 5. Interacting pathway analysis.** Illustration of the most expressed genes in the microarray of FoxM1-depleted cells, which included cell cycle regulators and DNA repair-related pathways. The input list genes are in gray; unfilled forms represent genes that were not part of the input list. The different symbols represent enzymes (diamonds), kinases (triangle), transcription factors (oval), not classified (circle), and protein complex (double circle). The figure was adapted from IPA software (Ingenuity Systems).

doi:10.1371/journal.pone.0048160.g005

| Table 2. Molecular functions altered by FoxM1 inhibition. |
|-----------------|-----------------|-----------------|
| **Name**        | **p-value**     | **# Molecules** |
| Cell Cycle      | $4.95\times10^{-11}$–$3.18\times10^{-2}$ | 232 |
| Cellular Assembly and Organization | $1.36\times10^{-10}$–$3.18\times10^{-2}$ | 153 |
| DNA Replication, Recombination, and Repair | $1.36\times10^{-10}$–$2.97\times10^{-2}$ | 210 |
| Cellular Function and Maintenance | $9.62\times10^{-7}$–$3.18\times10^{-2}$ | 52 |
| Post-Translational Modification | $1.25\times10^{-6}$–$8.61\times10^{-3}$ | 175 |

Data from IPA software (Ingenuity Systems).
doi:10.1371/journal.pone.0048160.t002
Table 3. Cellular functions altered by FoxM1 inhibition.

| Name                              | p-value | Ratio |
|-----------------------------------|---------|-------|
| Protein Ubiquitination Pathway    | 6.42E-15| 65/274 (0.237) |
| Role of BRCA1 in DNA Damage Response | 1.7E-10 | 23/61 (0.377) |
| DNA Double-Strand Break Repair by Homologous Recombination | 6.84E-07 | 9/17 (0.529) |
| Hereditary Breast Cancer Signaling | 7.01E-06 | 26/129 (0.202) |
| Mitotic Roles of Polo-Like Kinase  | 3.46E-05 | 16/64 (0.25) |

*Data from IPA software (Ingenuity Systems).*

doi:10.1371/journal.pone.0048160.t003

and FoxM1 have been directly related to the Shh pathway, we hypothesized that increased genomic instability may be related to increased FoxM1 expression during CML evolution. However, patient analyses must be performed to verify this hypothesis. Therefore, our results indirectly suggest that FoxM1 could be involved in CML disease evolution.

Our study provides the identification of FoxM1 as a new STAT3 gene target and clarifies its role in proliferation, survival, drug resistance and DNA repair in chronic myeloid leukemia. However, the elucidation of the signaling pathways involved in FoxM1 expression in chronic myeloid leukemia might be useful to elucidate new strategies for treatment, drug resistance, prognosis and disease progression.

Materials and Methods

Cell lines & Drug treatment

The K562 cell line, established from a CML patient in blast crisis [40], was maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (HyClone), 100 U/ml penicillin (Invitrogen), 100 mg/ml streptomycin (Invitrogen) at 37°C in 5% CO2. The K562 cells were used as a BCR-ABL-positive cell line. The establishment of a K562 cell line resistant to the chemotherapeutic imatinib, K562-R, was described by [41]. The drug LLL-3 was used to inhibit STAT3, and imatinib (Novartis) was used to therapeutic imatinib, K562-R, was described by [41]. The drug LLL-3 was used as a vehicle control. LLL-3 was kindly provided by Dr. Pui-Kai Li from Ohio State University, Columbus, USA.

Real-Time quantification PCR (RT-qPCR)

Total RNA was isolated using TRIzol reagent (Invitrogen), according to the manufacturer’s instructions. The purified RNA samples were reverse-transcribed using a SuperScript III First Strand Synthesis kit (Invitrogen) with oligo dt (dIT) following the manufacturer’s recommendations. The newly synthesized cDNA was diluted 10-fold in TE (Tris-HCl 10 mM pH 8.0 and EDTA 1 mM) buffer and used for RT-qPCR analysis. The PCR reactions were performed for each sample and analyzed in triplicate. The RT-qPCR was performed using a 1X Power SYBR Green Master Mix, 0.2 μM of each primer and 1.0 μL of the cDNA sample. The reaction was loaded into a Rotor Gene Q (Qiagen), and the following program was executed: an initial cycle at 95°C for 10 min, followed by 45 cycles of 95°C for 15 s and 60°C for 1 min. The relative gene expression levels were determined using the ΔΔCt method (2−ΔΔCt) [42]. The ACTNB mRNA level was used as a reference to normalize the reactions. The following primers were used: FoxM1 sense: 5′-GACCTGTCGGGGTGTTGGGGTGTG-3′ and antisense: 5′-GGAGGAAATGCTTCAAGGGC-3′; STAT3 sense: 5′-GGAGAAGAGGGTG-3′; and antisense: 5′-CTGATGTCGG-3′.

Electrophoretic Mobility Shift Assays (EMSA)

For the EMSA experiments, double-strand DNA oligonucleotides were synthesized based on the FoxM1 sequences from the upstream promoter region, which contained the STAT3 consensus binding site (underlined). FoxM1: 5′-GTTGGACAT-3′ and antisense: 5′-CCGCAGTTGSGTATGGCAGCTC-3′; and antisense: 5′-CTCGGATACTGCTTCCTCAG-3′ and antisense: 5′-GGGGAAAATTCAGAGGAATC-3′.

GTC-3′ and antisense: 5′-AGACAGCACCAGTGTGGGGC-3′.

Chromatin immunoprecipitation assay

To determine the in vivo binding of STAT3 to the FoxM1 promoter DNA sequence, chromatin immunoprecipitation (ChIP) assay was performed [43]. Briefly, 1 x 10⁶ K562 cells were fixed in 1% formaldehyde for 10 min to crosslink the DNA and the DNA-associated-proteins. The reaction was quenched using 125 mM glycine for 5 min. The cell pellet was washed three times in cold PBS 1X and reconstituted in RIPA buffer containing Protease Mix Inhibitor (Amersham). The cell lysate was sonicated for 3 min with 5 s pulse intervals on a Misonix 3000 sonicator (Misonix), pre-cleared and incubated with 5 μg of anti-STAT3 antibody (sc-482, C20, Santa Cruz) or a normal rabbit IgG antibody (sc-2027, Santa Cruz) followed by an isolation procedure using Protein-A/G Sepharose Beads (GE Healthcare). The beads were washed, and the DNA-protein interaction was reversed by heating to 65°C for 12 h [44]. The DNA was precipitated with ethanol and reconstituted in MillQ water. The purified immunoprecipitated DNA fragment was amplified by PCR. The primer sequences flanking the STAT3 bind consensus sequence of the FoxM1 promoter are as follows: 5′-GTAGGGTTCATGGTGCCGACA-3′ and 5′-CGCGGTTCAGTTGAGTTTTCGTCC-3′. The PCR reactions and thermal cycling were performed equally as above mentioned in the “Real-Time PCR” section. The percentage of STAT3 binding (N%) was calculated using the following formula: N% = exp(2ΔCtinput − ΔCtSTAT3), in which Ctinput and...
**Luciferase Reporter Assay**

Luciferase Reporter Assay: The plasmids used for this experiment are as follows: pGL3-Promoter Vector, pGL3-plasmid containing FOXM1 DNA promoter region (−466/+39) and plpRTK renilla luciferase expression plasmid was used as an internal control (Promega). The DNA FOXM1 promoter region was amplified using the following primers: FOX1P−466/+39 sense 5′-AGATAATACGCGAGCTCAAAAGG AAAGG-3′ and FOX1P+39 antisense 5′-TTTGGCAAGGAGCTTCAAGG-3′. PCR products were digested with BgiII and KspI (Promega) and inserted into a pGL3-Promoter Vector using T4 DNA ligase (Invitrogen). The recombinants were transformed and grown. Colonies were confirmed by PCR amplification using pGL3 control primers (Promega), and plasmid mini-preparations were performed with a Wizard® Plus SV Miniprep DNA Purification System (Promega). We co-transfected 0.2 µg of pGL3-Promoter Vector or pGL3-FoxM1 (−466/+39) with 0.2 µg of pRL-TK Renilla plasmid in K562 cells with Lipofectamine LTX with Plus Reagent (Invitrogen). After 24 h, K562 cells were treated with 40 µM LLI-3 or 1 µM imatinib for 24 h. Luciferase assay quantification was performed with a Dual-Luciferase® Reporter Assay System (Promega) and a Veritas Microplate Luminometer (Promega). Luciferase activity in treated or untreated cells was normalized for transfection efficiency to Renilla activity, and the results were indicated as fold induction in comparison to the cells transfected with empty pGL3-Promoter Vector. All results are representative of at least three independent experiments and represent the mean ± S.D. of triplicate samples.

**RNA interference of FOXM1 transcript**

The K562 cells were plated at 1 × 10⁵ cells/ml in a 24-well plate and left overnight in RPMI-1640 media without antibiotics before the transfections assays. FoxM1 siRNA was synthesized by Integrated DNA Technology (IDT) based on previously published sequences, 5′-GGACACAUUUCGCCAAGUUG-3′ [8,45]. A concentration of 10 nM of the scrambled siRNA (SC-37007, Santa Cruz) was used as a siRNA negative control. The transfection efficiency was evaluated using transfections of FITC-conjugated siRNA (SC-36869, Santa Cruz) and analyzed by flow cytometry. The siRNA transfections were performed using 10 nM Trifectin according to the manufacturer’s protocol (Promega). The siRNA transfections were conducted for up to 72 hours.

**Cell proliferation, Viability and Cell Cycle Analysis**

The proliferation assay was conducted using 1 × 10⁵ K562 cells/ml of cells transfected with scrambled siRNA or siRNA-FoxM1 in a 24-well plate for 24 h. Subsequently, the cells were stained with 0.1% trypan blue and counted in quadruplicate with a Neubauer chamber. The non-viable cells were excluded by trypan blue staining. The relative number of cells was expressed as a percentage of the siRNA transfections compared with the untransfected cells. Cell viability was evaluated by detecting early apoptosis via annexin V-FITC staining (BD Bioscience) analysis. Briefly, the K562 cells were harvested in 500 µL of binding buffer (10 mM Hepes [pH 7.4]; 150 mM NaCl; 5 mM KCl; 1 mM MgCl₂ and 1.8 mM CaCl₂), stained with 1 µL of fluorescein-labeled annexin-V-FITC, followed by a 20-min incubation in the dark. Propidium iodide (1.5 µg/ml) was added to the incubated tubes prior to analysis. Ten thousand events were collected from each sample in a FACScalibur Flow Cytometer (BD Bioscience). Annexin V-FITC (+), PI (−) cells were considered apoptotic events. Cell cycle analysis was performed by DNA distribution and was analyzed using propidium iodide (PI; Sigma–Aldrich), as described by Nicoletti et al. The cultured cells were subjected to different treatments and were washed in phosphate-saline buffer, reconstituted in 300 µL of hypotonic buffer (0.1% sodium citrate; 0.1% Triton-X; 100 µg/mL RNase and 50 µg/mL PI) and incubated for 30 min at 4°C.

**Microarray assay and results analysis**

Total RNA was extracted using TRIzol Reagent (Invitrogen) and purified by RNeasy (Qagen) according to the manufacturer’s instructions. The total RNA (1 µg) was reverse transcribed and then used to produce biotinylated cRNA using a GeneChip whole transcription (WT) sense target-labeling assay (Affymetrix). The biotinylated cRNA was then hybridized to the GeneChip human exon 1.0 ST array (Affymetrix), which was washed and stained according to the manufacturer’s protocols. The GeneChip arrays were scanned using a GeneChip® Scanner 3000, and Affymetrix Expression Console Software Version 1.0 was used to create the summarized expression values. The data were analyzed using Partek® software (http://www.partek.com); a differential expression of at least a 2-fold change was used to define up- and down-expression. Functional grouping and pathway analysis from differential expressed genes were processed and visualized by Ingenuity Pathways Analysis (IPA) (Ingenuity® Systems).

**Supporting Information**

Figure S1 PCR amplification of predicted STAT3 binding sites from immunoprecipitated FoxM1 DNA promoter. Bars represents the means (± standard deviation) of FoxM1 DNA promoter amplification regions from −850 to −214 base pairs (bp – green bar); −626 to −214 bp (pink bar); −466 to −214 bp (purple bar). Positive control of STAT3 ChIP, promoter of CDC25A gene (−222/−48 bp – dark blue bar); Negative control of ChIP, internal DNA sequence of FoxM1 gene (+1789/+1947 bp – light blue bar). IgG: immunoglobulin G.

(TIF)

Figure S2 Comparison and confirmation of altered genes found in RT-qPCR and Microarray from siRNA to FoxM1 gene: Bars represents the means (± standard deviation) of relative mRNA levels of CCNB1, CDC25B, SKP2 and AURKA genes. Scrambled siRNA (white bars); RT-qPCR assay (black bars); Microarray assay (gray bars).

(TIF)

Figure S3 Biofunctions downregulated by FoxM1 inhibition: Bars represents the most representative biological functions regulated negatively in response to depletion of FoxM1 by siRNA. Data was adapted from from IPA software (Ingenuity Systems).

(TIF)
Figure S4  Biofunctions upregulated by FoxM1 inhibition.
Bars represents the most representative biological functions regulated positively in response to depletion of FoxM1 by siRNA.
Data was adapted from from IPA software (Ingenuity Systems).

Table S1  Excel file with list of altered genes in FoxM1 siRNA assay.

References
1. Le Lay J, Kaestner KH (2010) The Fox genes in the liver: from organogenesis to functional integration. Physiol Rev 90: 1–22.
2. Wang M, Gartel AL (2011) The suppression of FOXM1 and its targets in breast cancer xenografts utilizes siRNA. Oncotarget 2: 1218–26.
3. Yoshida Y, Wang JC, Yoder HM, Davidson NO, Costa RH (2007) The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132: 1420–31.
4. Kim JM, Ackerson T, Ramakrishna S, Trejоловa M, Wang JC, et al. (2006) The Forkhead Box M1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res 66: 2153–61.
5. Priller M, Poschl D, Albrecht L, von Buuren AO, Ciof YJ, et al. (2011) Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res 17: 6791–801.
6. Liu M, Dai B, Kang SH, Ban K, Huang FJ, et al. (2006) FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenesis of glioma cells. Cancer Res 66: 3593–602.
7. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH (2007) Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis in pancreatic cancer cells. Cancer Res 67: 8293–300.
8. Nakamura S, Hiran o I, Okai K, Takemura T, Yokota D, et al. (2010) The FOXM1 transcriptional factor promotes the proliferation of leukemia cells through modulation of cell cycle progression in acute myeloid leukemia. Carcinogenesis 31: 2012–21.
9. Carr JR, Park HJ, Wang Z, Kiefer MM, Raychaudhuri P (2010) FOXM1 mediates resistance to herceptin and paclitaxel. Cancer Res 70: 5034–63.
10. Yang DK, Son CH, Lee SK, Choi DJ, Lee KE, et al. (2009) Forkhead Box M1 expression in primary squamous cell carcinoma: correlation with clinical-pathologic features and its prognostic significance. Hum Pathol 40: 464–70.
11. Martin KJ, Patrick DR, Bissell MJ, Fournier MV (2008) Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 20: e2994.
12. Kato Y, Kato M (2005) Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther 4: 1050–4.
13. Douard R, Moutereau S, Pernet P, Chimingqi M, Allory Y, et al. (2006) Sonic hedgehog-dependent proliferation in a series of patients with colorectal cancer. Surgery 139: 665–70.
14. Laurendeau I, Ferrer M, Garrido D, D’Haene N, Ciavarelli P, et al. (2010) Gene deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch pathways during development of lung cancer. Cancer Res 66: 2153–61.
15. Martin KJ, Patrick DR, Bissell MJ, Fournier MV (2008) Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS One 20: e2994.
16. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, et al. (2005) Raf/MEK/MAPK signaling stimulates the nuclear translocation and transcriptional and transactivating activity of FOXM1c. J Cell Sci 118: 795–806.
17. Kato Y, Kato M (2009) Hedgehog target genes: mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr Mol Med 9: 873–86.
18. Ma KY, Tong TH, Cheung AM, Tsang AC, Leung WY, et al. (2005) Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci 118: 795–806.
19. Ma KY, Tong TH, Leung WY, Yao KM (2010) Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1. Methods Mol Biol 647: 113–23.
20. Masuda M, Wakisako T, Suzui M, Tei S, Joe A, et al. (2010) Stat3 orchestrates tumor development and progression: the Achilles’ heel of head and neck cancers? Curr Cancer Drug Targets 10: 117–26.
21. Mencalha AL, Du Rocher B, Salles D, Binato R, Abdellah E (2011) A STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate. Cancer Chemother Pharmacol 65: 1039–46.
22. Coppo P, Flamant S, De Mas V, Jarrier P, Guillier M, et al. (2006) BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 134: 171–9.
23. Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, et al. (2007) Derepression and cross talk among Sonic hedgehog, Wnt, Hex and Notch signaling in chronic myeloid leukemia progression. Leukemia 21: 949–55.
24. Bae B, Vigneron A, Coqueret O (2005) The STAT3 transcription factor is a target of the Myc and ribosomal proteins on the Cdk25A promoter. J Biol Chem 280:15673–81.

Acknowledgments
We thank the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ministério da Saúde, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ).

Author Contributions
Conceived and designed the experiments: ALM RB BD EA. Performed the experiments: ALM RB BD EA. Contributed reagents/materials/analysis tools: ALM EA. Wrote the paper: ALM EA.